drugset / Trial / NCT07321912
Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
Phase 2
Recruiting
406 enrolled
Milton S. Hershey Medical Center
USWM, LLC (dba US WorldMeds) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Ewing sarcoma (EWS) and osteosarcoma primarily affect adolescents and young adults. Common treatments include chemotherapy, surgery and radiation, however, there have been few recent advancements in the standard of care. By incorporating eflornithine (DFMO) as an additional therapy and/or maintenance therapy we hope to safely observe improved event-free survival and overall survival. There are 5 cohorts covered under this master protocol.
Timeline
- Start
- 2026-06-05
- Primary completion
- 2031-06-01
- Completion
- 2036-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eflornithine | Small molecule | — | Oral |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Doxorubicin | Other / unclassified | — | — |
| Background | Etoposide | Small molecule | — | — |
| Background | Ifosfamide | Small molecule | — | — |
| Background | Methotrexate | Small molecule | — | — |
| Background | Topotecan | Small molecule | — | — |
| Background | Vincristine | Small molecule | — | — |